ClinicalTrials.gg
CompletedNCT02770365Updated Nov 2, 2021Results posted

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

A Phase 3 interventional study of estrace cream (Perrigo) and estrace cream (Reference) in Atrophy, sponsored by Padagis LLC. Completed at 1 site in United States. Open to female participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
695
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Atrophy with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Atrophy · United States.

Enrollment
Largest of 24
695 · median 42
Started
2016
with 1 other
Phase 3
4 of 29
none open now
Registered
13th of 29
by date

Among the 29 studies in Atrophy with a site in United States, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 13th registered.

Atrophy

126 studies on the registry are indexed under Atrophy; 22 are open to participants now.

Browse Atrophy studies →

Open to participants now

6 of the 29 studies in Atrophy with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Atrophy studies recruiting now, 5 (36%) set no upper age limit and 4 (29%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 30 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Atrophy with a site in United States, or all of them as a file.
02

Study summary

To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.

03

Conditions studied

  • Atrophy

Browse trials for

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female and otherwise healthy, 30 - 75 years of age.
  • ≤ 5% superficial cells on vaginal smear cytology at Visit 1/Screening.
  • vaginal pH > 5.0 at Visit 1/Screening
  • Have at least one self-assessed moderate to severe symptom of Vulvar and Vaginal Atrophy identified by the subject as being the most bothersome
  • For women with an intact uterus, vaginal ultrasonography confirmation at Visit 1/Screening of an inactive endometrial lining with an endometrial thickness less than 4 mm.
  • Systolic blood pressure no greater than 150 mm Hg and diastolic blood pressure no greater than 90 mm Hg at Visit 1/Screening and at Visit 2/Randomization

Exclusion criteria

Exclusion Criteria:

  • Undiagnosed vaginal bleeding or a history of significant risk factors for endometrial cancer.
  • Known, suspected, or history of cancer of the breast or mammogram indicating any abnormalities or subject has a history of cervical cancer.
  • Vaginal ultrasonography for all women with an intact uterus confirming endometrial thickness of 4mm or more
  • History of or allergy to estradiol or any of the other study medication ingredients.
  • Known or suspected estrogen-dependent neoplasia.
  • Has deep vein thrombosis, pulmonary embolism or history of these conditions.

    • Subject has active arterial thromboembolic disease (e. g. stroke, myocardial infarction) or history of these conditions.
  • Known acute or chronic hepatic disease or dysfunction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
695 participants (actual)

Study arms

  • Experimental
    Test Product

    estradiol cream

    Drug: estrace cream (Perrigo)

  • Active comparator
    Reference Product

    estradiol cream

    Drug: estrace cream (Reference)

  • Placebo comparator
    Placebo product

    Placebo cream

    Drug: Placebo cream

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Identified as Responders

    A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH \< 5.0 with a change from Visit 1 of at least 0.5.

    Time frame: Day 8

Secondary outcomes

  1. Most Bothersome Symptom

    Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.

    Time frame: Day 8

07

Results

Posted Aug 11, 2020

Participant flow

Participant flow — Overall Study
MilestoneTest ProductReference ProductPlacebo Product
Started277279139
Completed272275139
Not completed540

Outcome measures

PrimaryPercentage of Subjects Identified as Responders

A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH \< 5.0 with a change from Visit 1 of at least 0.5.

Time frame:
Day 8
Reported as:
Number · percentage of responders
Percentage of Subjects Identified as Responders
percentage of respondersTest ProductReference ProductPlacebo Product
Percentage of Subjects Identified as Responders36.832.00.8
Statistical analysis
  • Test Product vs Reference Product · Wald's method · Equivalence ratio: 1.14 · 90% CI -2.92 to 12.53
SecondaryMost Bothersome Symptom

Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.

Time frame:
Day 8
Reported as:
Count of participants · Participants
Most Bothersome Symptom
ParticipantsTest ProductReference Product
Most Bothersome Symptom116123
Statistical analysis
  • Test Product vs Reference Product · Wald's method · p = 0.05 · Equivalence ratio: 0.94 · 90% CI -12.35 to 4.31

Adverse events

Collected over 8 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/277 (0%)0/277 (0%)0/277 (0%)
Reference Product0/279 (0%)0/279 (0%)0/279 (0%)
Placebo Product0/139 (0%)0/139 (0%)0/139 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test ProductReference ProductPlacebo ProductTotal
Mean60.3 ± 6.3559.9 ± 6.3159.2 ± 6.0659.9 ± 6.28
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductReference ProductPlacebo ProductTotal
Female275277139691
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
Hispanic or Latino555929143
Not Hispanic or Latino220218110548
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
American Indian or Alaska Native0000
Asian85013
Native Hawaiian or Other Pacific Islander0101
Black or African American33352593
White233235114582
More than one race1001
Unknown or Not Reported0101
08

Study locations

1 site
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 3 years 9 months after primary completion. A results delay was requested in Dec 2016.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2016
First posted
May 12, 2016
Start
May 2016
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results delay requested
Dec 15, 2016
Results first posted
Aug 11, 2020
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02770365
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
May 12, 2016
Start date
May 2016
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Aug 11, 2020
Last update
Nov 2, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion